Contribution: Industrial Research Assistance Program
Rane Pharmaceutical Inc.
$144,000.00
Advancing a Selective EGFR-TKI Inhibitor to Overcome Drug Resistance in Lung Cancer
FY 2026-27 · 2026-06-01
Summary
Rane Pharmaceutical is developing novel small molecule therapy to treat drug resistant Non-Small Cell Lung Cancer (NSCLC). Over 30,000 Canadians are diagnosed annually with this type of lung cancer. Conventional treatments face drug resistance which remains a major barrier with no current secondary options. Having validated novel compounds, Firm intends to develop a therapeutic that addresses a massive unmet need of cancer drug resistance.
Department
Program
Industrial Research Assistance Program
Recipient
Location
Edmonton|Edmonton, Alberta, Canada
Recipient Type
For-profit organization
Business Number
737930321
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
As published
Agreement End Date
2027-05-31
Agreement Number
1043904
Agreement Start Date
2026-06-01
Agreement Title
Advancing a Selective EGFR-TKI Inhibitor to Overcome Drug Resistance in Lung Cancer
Agreement Title (French)
Développement d’un inhibiteur sélectif de l’EGFR-TKI pour surmonter la résistance aux médicaments dans le cancer du poumon
Agreement Type
Contribution
Agreement Value
$144,000.00
Amendment Number
0
Coverage
Industrial Research Assistance Program projects stimulate wealth creation for Canada through technological innovation and strengthen Canadian innovation ecosystem by creating new industrial capacity. | Les projets du Programme d'aide à la recherche industrielle favorisent la création de richesse au Canada grâce à l'innovation technologique et renforcent l'écosystème canadien de l'innovation en créant de nouvelles capacités industrielles.
Description
Rane Pharmaceutical is developing novel small molecule therapy to treat drug resistant Non-Small Cell Lung Cancer (NSCLC). Over 30,000 Canadians are diagnosed annually with this type of lung cancer. Conventional treatments face drug resistance which remains a major barrier with no current secondary options. Having validated novel compounds, Firm intends to develop a therapeutic that addresses a massive unmet need of cancer drug resistance.
Description (French)
Rane Pharmaceutical développe un nouveau traitement à base de petites molécules destiné à traiter le cancer du poumon non à petites cellules (CPNPC) résistant aux médicaments. Plus de 30 000 Canadiens reçoivent chaque année un diagnostic de ce type de cancer du poumon. Les traitements conventionnels se heurtent à une résistance aux médicaments qui reste un obstacle majeur, sans option thérapeutique alternative disponible à l’heure actuelle. Après avoir validé de nouveaux composés, l’entreprise entend développer un traitement répondant à un besoin médical non satisfait majeur lié à la résistance aux médicaments anticancéreux.
Expected Results
The expected results and outcomes of NRC Industrial Research Assistance Program is focused on growing small and medium-sized enterprises (SMEs) through innovation and wealth creation for Canada.
Expected Results (French)
Les résultats attendus du Programme d’aide à la recherche industrielle du CNRC sont axés sur la croissance des petites et moyennes entreprises (PME) grâce à l’innovation et à la création de richesse pour le Canada.
Federal Riding
Edmonton Mill Woods
Federal Riding (French)
Edmonton Mill Woods
Federal Riding Number
48017
NAICS Code
541720
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program
Program Name (French)
Programme d’aide à la recherche industrielle
Program Purpose
The purpose of Industrial Research Assistance Program Contributions to Firms is to provide support that assists small and medium-sized enterprises (SMEs) to advance their innovation knowledge and ability to innovate, grow through innovation and stimulate wealth creation for Canada.
Program Purpose (French)
Les contributions versées aux entreprises en vertu du Programme d’aide à la recherche industrielle ont pour objectif d’apporter un soutien aux petites et moyennes entreprises (PME) afin qu’elles puissent approfondir leurs connaissances en matière d’innovation et renforcer leur capacité d’innovation, de croissance et de création de richesse pour le Canada.
Recipient Business Number
737930321
Recipient City
Edmonton|Edmonton
Recipient Country
CA
Recipient Legal Name
Rane Pharmaceutical Inc.
Recipient Postal Code
T6E 5V2
Recipient Province or Territory
AB
Recipient Type
F
Reference Number
172-2026-2027-Q1-1043904
